Restriction Isotyping of Apolipoprotein E
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
I read with interest the review by Walden and Hegele [1]. The authors state that “apolipoprotein (apo) E is divided into two independently folded domains with different functions.” The boundary between these two domains is the random-coil region spanning amino acids 165 to 201, which is subject to enzymatic cleavage [2]. Thus, the region encompassing approximately the first 160 to 210 amino acids contains the apo B-E receptor-binding domain (which is located approximately between amino acids 130 and 160), whereas the C-terminal region mediates the binding to lipids.
Evidence now suggests that apolipoproteins do specifically bind thyroid hormones with medium affinity [3-5]. Such a hormone interaction may serve several biological functions [4]. Studies of apo A-I and apo E have shown that the location is N-terminal and that it coincides with the respective exon 3-coded region of both apolipoproteins. Sequences of particular relevance to this hormone-binding function are those having the predicted secondary structure of a β-sheet (amino acids 32 to 44 in apo E and amino acids 9 to 23, 28 to 33, and 43 to 47 in apo A-I). By contrast, the secondary structure of the lipid-binding region is the amphipathic α-helix in the form of a 22-mer repeating unit. This location of the hormone site of apolipoproteins is supported by the recent finding that the exon 3-coded regions not only of apo A-I and apo E but also of the other apolipoproteins of the high-density lipoproteins share sequence homology with the regions of the three major thyroid hormone plasma transport proteins (thyroid-binding globulin, transthyretin, and albumin) known or postulated to contain the respective thyroid hormone sites [5]. The N-terminal position of the thyroid hormone site explains why the amino acid mutations at position 112 (apo E4) or 158 (E2) leave intact the thyroid hormone-binding property.
It can be concluded that the domain constituted by the first 160 to 210 residues is composed of three subdomains: the hormone-binding subdomain (approximately the first 61 amino acids), the apo B-E receptor-binding subdomain (approximately amino acids 130 to 160) and a lipid-binding subdomain between them. It seems more logical (and more justified on genetic grounds), however, to consider apo E (and the other high-density lipoprotein apolipoproteins) as comprising two distinct domains: the exon 3-coded domain and the exon-4 coded domain. The first represents the thyroid hormone-binding domain, and the second consists of the lipid-binding domain (amino acids 62 to 299 in apo E). In apo E, however, this domain evolved to contain a specialized region that interacts with the apo B-E receptor and that can be viewed as a subdomain separating two flanking lipid-binding subdomains.
Salvatore Benvenga, MD
National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Bethesda, MD 20892
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
RSS Feeds









